Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025
Elite Pharmaceuticals (OTCQB: ELTP) will release its second quarter fiscal 2026 financial results for the period ended September 30, 2025 on Friday, November 14, 2025. Management will host a live conference call on Monday, November 17, 2025 at 11:30 AM EST to review financial and operating results and provide a business update. Stockholders are encouraged to submit questions in advance by the stated deadlines.
Call details: domestic dial-in 1-800-346-7359, international 1-973-528-0008, conference number 98840. Audio replay will be available at https://elite.irpass.com/events_presentations.
Elite Pharmaceuticals (OTCQB: ELTP) sarà comunicato i risultati finanziari del secondo trimestre fiscale 2026 per il periodo terminato 30 settembre 2025 in venerdì 14 novembre 2025. La direzione terrà una conferenza telefonica in diretta il lunedì 17 novembre 2025 alle 11:30 AM EST per esaminare i risultati finanziari e operativi e fornire un aggiornamento sull'attività. Agli azionisti è incoraggiato inviare domande in anticipo entro le scadenze indicate.
Dettagli della chiamata: interno 1-800-346-7359, internazionale 1-973-528-0008, numero di conferenza 98840. Il replay audio sarà disponibile su https://elite.irpass.com/events_presentations.
Elite Pharmaceuticals (OTCQB: ELTP) publicará sus resultados del segundo trimestre fiscal de 2026 para el periodo terminado el 30 de septiembre de 2025 el viernes 14 de noviembre de 2025. La dirección realizará una conferencia telefónica en vivo el lunes 17 de noviembre de 2025 a las 11:30 AM EST para revisar los resultados financieros y operativos y proporcionar una actualización comercial. Se anima a los accionistas a enviar preguntas por adelantado antes de las fechas límite indicadas.
Detalles de la llamada: marcación doméstica 1-800-346-7359, internacional 1-973-528-0008, número de conferencia 98840. La reproducción de audio estará disponible en https://elite.irpass.com/events_presentations.
Elite Pharmaceuticals (OTCQB: ELTP)는 2025년 9월 30일 종료되는 2026 회계연도 2분기 실적을 2025년 11월 14일 금요일에 발표합니다. 경영진은 2025년 11월 17일 월요일 오전 11:30 EST에 라이브 컨퍼런스콜을 개최하여 재무 및 운영 실적을 검토하고 사업 업데이트를 제공합니다. 주주들은 명시된 기한 내에 사전 질문을 제출하는 것이 권장됩니다.
통화 정보: 국내 전화 1-800-346-7359, 국제 1-973-528-0008, 컨퍼런스 번호 98840. 오디오 재생은 https://elite.irpass.com/events_presentations에서 이용 가능합니다.
Elite Pharmaceuticals (OTCQB: ELTP) publiera ses résultats financiers du deuxième trimestre fiscal 2026 pour la période se terminant le 30 septembre 2025 le vendredi 14 novembre 2025. La direction organisera une conférence téléphonique en direct le lundi 17 novembre 2025 à 11h30 EST afin d'examiner les résultats financiers et opérationnels et de fournir une mise à jour sur l'activité. Les actionnaires sont invités à soumettre leurs questions à l’avance avant les délais indiqués.
Détails de l'appel : appel national 1-800-346-7359, international 1-973-528-0008, numéro de conférence 98840. La reproduction audio sera disponible sur https://elite.irpass.com/events_presentations.
Elite Pharmaceuticals (OTCQB: ELTP) wird seine Ergebnisse des zweiten Quartals des Geschäftsjahres 2026 für den Zeitraum bis zum 30. September 2025 am Freitag, dem 14. November 2025 veröffentlichen. Das Management wird am Montag, dem 17. November 2025 um 11:30 Uhr EST eine Live-Konferenzschaltung abhalten, um Ergebnisse und operatives Ergebnis zu besprechen und ein Geschäftsupdate zu geben. Aktionäre werden aufgefordert, Fragen im Voraus vor den angegebenen Fristen einzureichen.
Anrufdetails: Inland 1-800-346-7359, international 1-973-528-0008, Konferenznummer 98840. Die Audio-Wiederholung ist verfügbar unter https://elite.irpass.com/events_presentations.
إيـليت فارماسيوتيكالز (OTCQB: ELTP) ستُعلن عن نتائجها المالية للربع الثاني من السنة المالية 2026 للفترة المنتهية في 30 سبتمبر 2025 يوم الجمعة 14 نوفمبر 2025. ستعقد الإدارة مكالمة مؤتمرات مباشرة يوم الاثنين 17 نوفمبر 2025 الساعة 11:30 صباحاً بتوقيت شرق الولايات المتحدة لاستعراض النتائج المالية والتشغيلية وتقديم تحديث عن الشركة. يُشجَّع المساهمون على تقديم أسئلة مسبقاً قبل انتهاء المهلة المحددة.
تفاصيل الاتصال: داخلي 1-800-346-7359، دولي 1-973-528-0008، رقم المؤتمر 98840. ستتوفر إعادة الصوت على https://elite.irpass.com/events_presentations.
- None.
- None.
Financials for Second Quarter of Fiscal Year 2026 Ended September 30, 2025 will be released on Friday, November 14, 2025
Northvale, New Jersey--(Newsfile Corp. - November 10, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2026 fiscal year will be released on Friday, November 14, 2025. Elite's management will host a live conference call on Monday, November 17th, at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update. Stockholders should submit their questions to the company prior to the call.
| Date: | November 17, 2025 |
| Time: | 11:30 AM EST |
| Dial-in numbers: | 1-800-346-7359 (domestic) 1-973-528-0008 (international) |
| Conference number: | 98840 |
| Questions: | dianne@elitepharma.com General questions by 5:00 PM EST on Thursday, November 13, 2025 Financial questions by 7:00 PM EST on Friday, November 14, 2025 |
| Audio Replay: | https://elite.irpass.com/events_presentations |
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite's product lines consist of immediate-release and controlled-release, solid oral dose products, which are marketed under the Elite Laboratories label, as well as pursuant to licenses granted to third-party pharmaceutical marketing and distribution organizations. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties, and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273653
FAQ
When will Elite Pharmaceuticals (ELTP) release Q2 fiscal 2026 results?
When and at what time is the Elite Pharmaceuticals (ELTP) conference call?
How can shareholders submit questions for the ELTP November 17, 2025 call?
What dial-in numbers and conference ID do I use for the ELTP call on November 17, 2025?
Where can I listen to the audio replay of Elite Pharmaceuticals' November 17, 2025 call?
